Journey Medical Corporation has reported impressive financial results for the second quarter of 2026, marking a significant advancement in its operational and commercial objectives. The company witnessed a substantial 23% rise in total net product revenues compared to the previous year, primarily propelled by the burgeoning market presence and demand for its lead rosacea treatment, Emrosi. This period saw the company transition to positive EBITDA and adjusted EBITDA, alongside a notable reduction in its GAAP net loss, underscoring effective expense management and robust revenue generation.
Further solidifying its market position, Journey Medical has successfully expanded Emrosi's prescriber base, with unique dermatology prescribers increasing by over 40% since the end of 2025. The drug's prescription volumes escalated by 20% sequentially, demonstrating growing clinical adoption and patient satisfaction. Enhanced payer coverage and a rise in average selling prices, attributed to strategic negotiations with major health plans, further contributed to Emrosi's commercial momentum. Additionally, the company introduced Urox Cream, an anti-itch treatment, in July 2026, diversifying its dermatology portfolio and leveraging its established commercial infrastructure for sustained growth.
The company's strategic initiatives, including the expansion of its sales force and ongoing discussions for international out-licensing of its patented products, are designed to maximize market penetration and unlock additional value. Management expressed confidence in 2026 being a landmark year, characterized by both revenue expansion and profitability, as Journey Medical continues to focus on delivering innovative solutions to dermatology patients and healthcare providers while enhancing shareholder value.
Journey Medical's dedicated pursuit of excellence in product development and market strategy not only fosters growth and financial stability for the company but also significantly contributes to improving the quality of life for patients. This commitment to innovation and accessible treatment options exemplifies how business success can align with positive societal impact, creating a healthier future for all.
